epirubicin ebewe süste-/infusioonilahuse kontsentraat
sandoz pharmaceuticals d.d. - epirubitsiin - süste-/infusioonilahuse kontsentraat - 2mg 1ml 50ml 1tk; 2mg 1ml 100ml 1tk; 2mg 1ml 5ml 1tk
wamlox õhukese polümeerikattega tablett
krka, d.d., novo mesto - valsartaan+amlodipiin - õhukese polümeerikattega tablett - 80mg+5mg 56tk; 80mg+5mg 28tk; 80mg+5mg 30tk; 80mg+5mg 90tk; 80mg+5mg 60tk; 80mg+5mg 98tk; 80mg+5mg 100tk; 80mg+5mg 84tk
dipperam õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - valsartaan+amlodipiin - õhukese polümeerikattega tablett - 160mg+5mg 280tk; 160mg+5mg 30tk; 160mg+5mg 56tk; 160mg+5mg 28tk; 160mg+5mg 14tk; 160mg+5mg 90tk
farmorubicin pfs süste-/infusioonilahus
pfizer enterprises sarl - epirubitsiin - süste-/infusioonilahus - 2mg 1ml 5ml 1tk; 2mg 1ml 25ml 1tk
mayzent
novartis europharm limited - siponimod fumaarhape - sclerosis multiplex, relapsing-remitting - selektiivsed immunosupressandid - mayzent on näidustatud ravi täiskasvanud patsientidel, kellel on sekundaarse progresseeruva sclerosis multiplex (spms) aktiivne haiguse tõendab ägenemiste või kujutise omadused põletikuline aktiivsus.
enerzair breezhaler
novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - ravimid hingamisteede obstruktiivsete haiguste, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
bemrist breezhaler
novartis europharm limited - indacaterol, mometasone furoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - bemrist breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
atectura breezhaler
novartis europharm limited - indacaterol acetate, mometasone furoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
zimbus breezhaler
novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - maintenance treatment of asthma in adults whose disease is not adequately controlled.
dasatinib accordpharma
accord healthcare s.l.u. - dasatiniib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastilised ained - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.